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Aim: We aimed to estimate the societal treatment-related costs of COPD in hospital- and po-
pulation-based subjects with spirometry defined COPD, relative to a control group.
Methods: 81 COPD cases and 132 controls without COPDwere randomly recruited from a general
population, as were 205 COPD patients from a hospital register. All participants were ever-
smokers of at least 40 years of age, followed for 12 months. Data on comorbid conditions and
spirometry were collected at baseline. Standardized telephone interviews every third month
gave information on use of healthcare services and exacerbations of respiratory symptoms.
Results: The increased (excessive) median annual costs per case having stage II, stage III and
stage IV COPD wereV (95% CI) 400 (105e695), 1918 (1268e2569) and 1870 (1031e2709), respec-
tively, compared to the population-based controls. Costs increasedwithV81 (95% CI 50e112) per
exacerbation of respiratory symptomsandV461 (95%CI 354e567) per comorbid condition. Exces-
sive costs for hospital COPD patients were threefold that of the population-based COPD cases.
Conclusion: The excessive treatment-related cost of COPD stage IIþ in ever-smokers of at least
40 years was estimated to V105 million for Norway. Comorbidity was a dominant predictor of
excessive cost in COPD.
ª 2010 Published by Elsevier Ltd.of Thoracic Medicine, Lungeavdelingen, Haukeland University Hospital, N-5021 Bergen, Norway. Tel.:
.
o (R. Nielsen).
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Chronic obstructive pulmonary disease (COPD) is a disease
of high prevalence among smokers1 and is related to
significant morbidity and mortality.2 In terms of costs,
COPD places a considerable burden on healthcare systems
and societies worldwide.3,4
Cost of illness (COI) estimates on COPD vary due to
differing target populations, identification and selection of
COPD cases, study design, completeness of cost items,
utilization and pricing of healthcare services. The best
reflection of costs incurred by COPD, excessive costs,
implies estimating the effect of adding COPD to a baseline
level of resource utilization in a control population.5,6
Previous studies7e12 have considerable limitations
related to accuracy when reporting excessive costs of COPD.
Three studies did not adjust for comorbid diseases,7,9,10
while four were not population-based samples.8e11 One
study included only undiagnosed COPD subjects,10 whereas
the remaining studies excluded those without a COPD diag-
nosis. No studies but one12 adjusted estimates according to
tobacco smoking. Diseased subjects were identified
according to utilization of healthcare services, which
created a bias for higher costs. No study has previously
estimated excessive costs in spirometry verified COPD or
taken symptom defined exacerbations into account.
The Study of Economics in COPD (“EconCOPD”) was
a one-year prospective study gathering data on healthcare
utilization in COPD patients recruited from a university
hospital and population-based COPD cases and controls.13
We included ever-smokers only, to be able to isolate the
effects of COPD, and to reduce residual confounding when
adjusting for smoking habits. The study focused on clini-
cally relevant COPD, defined as stage II and higher
according to the classification of The Global Initiative for
Chronic Obstructive Lung Disease (GOLD).14
The aims of the current study were 1) to estimate
excessive treatment-related societal costs of COPD in ever-
smokers and 2) to compare costs in hospital-selected COPD
patients with those in randomly recruited COPD cases from
a community study.
Methods
The EconCOPD study took place from March 2005 to August
2006. All participating subjects provided written consent,
and The Regional Committee for Medical and Health
Research Ethics in Western Norway approved the study.
Details of sampling procedures and data collection have
been published previously.13
Population
The EconCOPD study consisted of three groups of partici-
pants e COPD cases and controls recruited from a pop-
ulation-based sample (“cases” and “controls”) and
randomly selected COPD patients treated at a university
hospital (“patients”) (E-Fig. 1). The latter group was
initially recruited to enlarge the number of cases with very
severe COPD. At baseline, all subjects were 40 years old
and reported 2.5 pack years of tobacco smoking. COPDwas defined by post-bronchodilator spirometry as a ratio of
forced expiratory volume in 1 s (FEV1) over forced vital
capacity (FVC) < 0.7 and FEV1 below 80% of predicted using
a Norwegian reference equation.15 Controls had FEV1/
FVC  0.7, and FEV1  80% of predicted. In total 205
patients, 81 cases and 132 controls completed one year of
follow-up. A further description of the three participant
groups is provided in the online supplement.
Data collection
Therewerefivecontactswithall participants.After abaseline
interviewat the outpatient clinic, subjectswere contacted by
telephone after 12, 24, 36 and 52 weeks for follow-up inter-
views. All interviewers were either healthcare professionals
(nZ 3) or medical students (nZ 6), and they received iden-
tical training in interviewing technique, including role play
and supervised interviews. Spirometry results were collected
from the database of the 2003e2005 follow-up of the Horda-
land County Respiratory Health Study (HCRHS), including
hospital-recruited COPDpatients.16 Level of lung function and
consecutive COPD-classification followed the GOLD stages.14
Questionnaires
The Obstructive Lung Diseases in Northern Sweden (OLIN)
COI-study questionnaire3 was used as a template. Questions
concerning smoking habits, educational level and respira-
tory symptoms were added from the Norwegian Respiratory
Questionnaire.17 The questions used for the current paper
are available in the online supplement.
At baseline we asked about smoking habits, gender, age,
educational level, comorbid conditions and drug use. At the
follow-ups, information concerning respiratory symptoms,
drug use and healthcare utilization was registered. An exac-
erbation of respiratory symptoms (ERS) was defined as an
event with 2 of 3 major symptoms (increased dyspnea,
increased phlegm, colour change of phlegm) or 1 major and 1
minor symptom (increased cough, sore throat, runny or stuf-
fed nose, increased wheezing in the chest, asthenia) for at
least two consecutive days (modified Anthonisen criteria18).
Comorbiditywasdefinedas anaffirmativeanswer toquestions
from a modified Charlsons index of comorbidity.19
Costs
We gathered information concerning contacts with health-
care providers (physicians, nurses, home healthcare
providers, physiotherapists), hospitalizations, rehabilita-
tion, drug use and home oxygen treatment. To obtain total
treatment-related costs, independent of which condition
that caused them, utilization was multiplied with unit
costs, which are presented in the online supplement. Costs
were transformed from 2006 NOK to Euros (V) using the
mean exchange rate for year 2006 (NOK 8.05 Z V1).20
Statistical analyses
We calculated sample size based on self-reported drug
costs from the baseline interview in a pilot study.21 To
detect a difference between groups of NOK 150 in drug
costs during 3 months, with a standard deviation of NOK
348, one would need 85 individuals in each group, assuming
significance level at 5% and power of 80%. The eligible
number of population-based cases was 111, while the
Excessive costs of COPD 487eligible number of controls was 492. Thus, for the control
group we were able to over-sample, to account for
expected drop-out and loss to follow-up. We invited 312
hospital-recruited COPD patients to increase precision for
estimates in subjects with severe and very severe COPD and
account for a larger expected drop-out in more severe
diseased participants. Details of the inclusion are given in
the online supplement.
Categorical variables were compared by chi-square
tests. Continuous variables were compared by t-tests,
analysis of variance (ANOVA), and non-parametric median
tests or ManneWhitney tests as appropriate. P-values
<0.05 were considered statistically significant.
Frequencies of healthcare utilization were multiplied
with the unit costs to obtain annual costs, and added for
each individual. Average and median estimates of unad-
justed treatment-related costs, irrespective of which
condition that caused utilization, were presented for each
of the three participant groups.
The cost distribution was right-skewed. There were
thirteen participants with zero treatment-related costs.
When costs were log-transformed, the data were still right-
skewed. Thus, we fitted two separate multiple median
regression models22 using quantile regression; one
comparing cases to controls and another comparing
patients to controls. Covariates included GOLD-stage,
smoking status, gender, age and educational level. Exces-
sive costs were the coefficients of the various GOLD stages
compared to having the lung function of a control subject.
To investigate effects of comorbidities and ERS these two
models were repeated adding number of comorbid condi-
tions and number of ERS events as covariates.
For all analyses we used Stata 10 and 11 SE for Macintosh
OS X (Stata Corp, College Station, TX).
Sensitivity analyses
In order to examine the robustness of our results, sensitivity
analyses were performed. Unit costs and frequencies of
utilization for hospitalization, medication and visits to
healthcare professionals were adjusted by 25% from the
base case analysis. Furthermore we examined outlier
effects by excluding participants with costs higher than the
95th percentile for the respective participant group.
Finally, we included subjects that withdrew from the
protocol or died, and investigated effects on our estimates
when they were allocated costs at 25% above or below the
median of their respective group.
Results
Characteristics
A representation of non-responses and drop-outs is
provided in the online supplement and in E-Fig. 1. Current
smokers and subjects with university education were less
common among the patients than in both population-based
groups (Table 1). The control group had smoked less in
terms of pack years than both the COPD groups. No gender
differences were observed. The hospital-recruited COPD
patients were older than participants in other groups. Lung
function was lower in patients than in the cases (p < 0.001).Comorbidities were more than twice as frequent in
hospital-recruited COPD patients, and 50% more frequent in
the population-based cases, compared with the controls.
There were more than twice as many ERS events in patients
than in population-based cases, whereas the controls
experienced only one fourth as many ERS events as the
cases did.
Healthcare utilization and unadjusted cost
estimates
Except for specialist visits and physiotheraphy, there was
a significant trend of more healthcare utilization going from
lowest utilization in controls via medium in cases to the
highest utilization in patients (p < 0.001) (Table 2). The
skewed distribution of healthcare utilization was overt for
all participant groups, except for number of drugs.
Unit costs for each healthcare service are given in E-
Table 1. Median total treatment-related costs and median
costs for major healthcare groups were significantly higher
for hospital patients than for population-based cases and
controls (Table 3, p < 0.01). Median total costs for cases
were more than twice the costs for the controls (Table 3,
p < 0.01), and median drug costs in cases were more than
threefold that of the controls (p < 0.001). We found no
significant difference between cases and controls con-
cerning costs of hospitalizations or contacts with health-
care professionals (p > 0.05). Annual median, total
treatment-related costs were 651% and 142% higher in
patients and cases, respectively, compared to the pop-
ulation-based controls (V612) (p < 0.001).
The internal distribution of mean costs per person in
patients, cases, and controls did not differ, and declined
from hospitalization (47e58%), drugs (22e28%), contacts
with healthcare professionals (14e20%) and pulmonary
rehabilitation (5e6%) to oxygen treatment (2%) (Table 2,
Fig. 1). In all three participant groups, drug utilization was
the group with the highest median unadjusted cost.
Multiple regression models
Disease severity
Table 4 presents two separate models estimating annual
treatment-related costs, adjusted for gender, age,
smoking, educational level and FEV1-level. The first model
(column 2) includes population-based COPD cases and
controls. The coefficients for various GOLD stages indicate
the excessive costs as compared to costs in control
subjects. When fitting the model without adjusting for
COPD severity, the excess median costs of COPD were (95%
CI) V918 (539e1297) (not shown).
In the secondmodel (third column, Table 4) we compared
patients with controls. The excessive costs of GOLD stage II,
III and IV COPDwere 251%, 72% and 292% higher, respectively,
compared with excessive costs of COPD in the first model.
When fitting this model without adjusting for COPD severity
the excess median costs of COPD were more than thrice that
of the comparison between cases and controls, reaching
V3340 (2859e3820) (not shown).
Female gender was associated with higher excess costs,
however, only significant in the first model, whereas age
Table 1 Characteristics at baseline and exacerbations of respiratory symptoms (ERS) during follow-up of 418 subjects,
according to participant status in EconCOPD study, Bergen, Norway.
Hospital-
recruited
COPD patients
Population-
recruited
COPD cases
Population-
recruited
controls
Statistic
N 205 81 132
Male, N (%) 123 (60) 53 (65) 69 (52) chi2, p Z 0.142
Age, mean years (SD) 66.8 (9.2) 63.5 (10.0) 57.1 (10.6) anova, p < 0.0001
Smoking habits
Ex-Smokers, N (%) 137 (67) 43 (53) 69 (52) chi2, p Z 0.012
Current smokers, N (%) 68 (33) 38 (47) 63 (48)
Pack years, mean (SD) 32.7 (31.0) 32.3 (35.6) 15.6 (12.3) kwallis p < 0.001
Education chi2 p < 0.001
Primary school, N (%) 75 (37) 32 (40) 27 (21)
Secondary school, N (%) 100 (49) 30 (37) 63 (48)
University, N (%) 30 (15) 19 (23) 42 (32)
Comorbidities, mean number
(SD) of conditions; median (iqr)
1.9 (1.5)
1 (3)
1.2 (1.5)
1 (2)
0.8 (1.0)
0 (1.5)
Kwallis p < 0.001
Lung function
FEV1 50e80% of predicted, N (%) 103 (50) 69 (85) 0 comparison
cases-patients: chi2,
p < 0.001
FEV1 30e50% of predicted, N (%) 68 (33) 8 (10) 0
FEV1 <30% of predicted, N (%) 34 (17) 4 (6) 0
FEV1, mean litres (SD) 1.48 (0.7) 2.2 (0.7) 3.3(0.7) kwallis p Z 0.0001
ERS during 12 months of follow-up, mean
(SD) number of events; median (iqr)
5.9 (6.1)
4 (8)
2.9 (6.2)
1 (3)
0.7 (1.5)
0 (1)
kwallis p < 0.001
Hospital-recruited COPD patients e selected COPD patients from the COPD register of a university hospital. Population-recruited COPD
cases e subjects with COPD from a population-based sample. Population-recruited controls e subjects without COPD, from a general
population. All participants were at least 40 years old, and were ever-smokers. COPD is defined as FEV1/FVC < 0.7 and FEV1 in %
predicted < 80%. Control subjects have FEV1/FVC  0.7 and FEV1% predicted  80%. ERS: 2 of 3 major symptoms (increased dyspnea,
increased phlegm, colour change of phlegm) or 1 major and 1 minor symptom (increased cough, sore throat, runny or stuffed nose,
increased wheezing in the chest, asthenia).
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model. Neither smoking habits, nor education was signifi-
cantly associated with healthcare costs.
Comorbidities and exacerbations
When the multiple regression models were re-fitted and
adjusted for number of comorbid conditions and ERS (online
supplement, E-Table 5), we found a cost of (95% CI) V81
(50e112) per ERS event, in the case-control model. The cost
per comorbid condition was estimated to V461 (355e567) in
the samemodel. The costs in the patient-controlmodelwere
V41 (8e73) andV633 (530e737) per ERS event and comorbid
condition, respectively. When fitting the model without
adjusting for COPD severity, but still adjusting for gender,
age, smoking habits, education, ERS and comorbidities, the
excess median cost of COPD (95% CI) was V581 (311e852)
(not shown), comparing cases to controls.
Sensitivity analyses
Excessive costs of COPD GOLD stage II and stage III were
most sensitive to the exclusion of individuals with costs
above the 95th percentile. For COPD GOLD stage IV, we
observed large changes in costs when we adjusted drug
costs by 25%. All sensitivity analyses are provided in the
online supplement.Discussion
We found that excessive treatment-related costs of COPD in
population-basedever-smoking caseswerealmost three times
higher in stage III and IV COPD, than in stage II COPD. The
excessive costs of COPD were reduced with 37% when adjust-
ing for comorbidities and ERS events. In a separate analysis
comparing COPD patients recruited from a hospital register to
population-based controls, excessive cost for hospital-treated
COPD was threefold that of the population-based cases.
COPD cases in our study were identified by including all
subjects that had GOLD-defined COPD, stage II or higher14
from a population-based sample. Previously, only the
OLIN COI-study has prospectively estimated costs of COPD
by spirometric screening of a population-based.3 They
included patients from only 14 different birth-years and
classified severity by pre-bronchodilator spirometry only. As
this study did not include control subjects, they were
unable to estimate excessive costs.
In a previous Norwegian study on healthcare utilization
in self-reported obstructive lung disease,23 utilization of
hospital services was comparable to a US study.12 The latter
found a large difference in costs between an attributable
cost approach and an excessive cost approach,12 which
might partly be explained with the excessive cost approach
capturing costs of comorbid diseases.
Table 2 Annual utilization of healthcare services according to participant status in EconCOPD, Bergen, Norway.
(N) Hospital-recruited
COPD patients
Population-
recruited
COPD cases
Population-
recruited
controls
Overall
statistics
Test for
trend
Hospitalization, all causes median test p < 0.001 p < 0.001
median no. of days (iqr) 0 (5) 0 (0) 0 (0)
total number of days in group 1113 151 177
Hospitalization, respiratory illness, median test p < 0.001 p < 0.001
median no. of days (iqr) 0 (0) 0 (0) 0 (0)
total number of days in group 472 1 5
Healthcare provider visits
GP visits median test p < 0.001 p < 0.001
median no of visits (iqr) 5 (6) 3 (5) 2 (3)
total number of visits in group 1424 404 407
Emergency room, visits median test p < 0.001 p < 0.001
median no of visits (iqr) 0 (1) 0 (0) 0 (0)
total number of visits in group 176 26 33
Specialist visits median test p Z 0.128 p Z 0.07
median no of visits (iqr) 0 (1) 0 (1) 0 (1)
total number of visits in group 208 74 208
Outpatient clinic at hospital median test p < 0.001 p < 0.001
median no of visits (iqr) 1 (2) 0 (2) 0 (0)
total number of visits in group 382 86 91
Physiotherapy median test p Z 0.685 p Z 0.735
median no of visits (iqr) 0 (0) 0 (0) 0 (0)
total number of visits in group 444 332 324
No. of drugs used during the
follow-up perioda
median test p < 0.001 p < 0.001
Median no. of drugs (iqr) 10 (7) 5 (6) 4 (5)
Total no. of drugs in group 2109 531 604
No. of prescribed drugs for
obstructive lung diseasesb
median test p < 0.001 p < 0.001
Median no. of drugs (iqr) 3 (2) 1 (2) 0 (0)
Total no. of drugs in group 627 108 12
Pulmonary rehabilitation,
training led by physiotherapist
median test p < 0.001 p < 0.001
Median no. of sessions 0 (1) 0 (0) 0 (0)
Total no. of sessions in group 2598 323 22
Pulmonary rehabilitation program Chi2 p < 0.001 p < 0.001
Median participation 0 (0) 0 (0) 0 (0)
Total no. of participants in group 28 3 0
Long term oxygen treatmentc chi2 p < 0.001 p < 0.001
Median oxygen use (iqr) 0 (0) 0 (0) 0 (0)
Total no. of oxygen users in group 19 0 0
Home nursing services median test p < 0.001 p < 0.001
Median number of hours 0 (0) 0 (0) 0 (0)
Total number of hours in group 1753 196 16
Maid servicesc chi2 p Z 0.001 p < 0.001
Median usage 0 (0) 0 (0) 0 (0)
Total number participants
using maid services
19 3 0
Hospital-recruited COPD patients e selected COPD patients from the COPD register of a university hospital. Population-recruited COPD
cases e subjects with COPD from a population-based sample. Population-recruited controls e subjects without COPD, from a general
population. All participants were at least 40 years old, and were ever-smokers. COPD is defined as FEV1/FVC < 0.7 and FEV1 in %
predicted < 80%. Control subjects have FEV1/FVC  0.7 and FEV1% predicted  80%.
Iqr e interquartile range (75th percentilee25th percentile).
a Includes over-the-counter medication.
b Inhaled corticosteroids, inhaled anticholinergics, B2-agonists, aminophyllines, leukotriene modifiers.
c Variable coded as 0/1 for all participants.
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Table 3 Annual unadjusted costs per person, by different healthcare services according to participant status in EconCOPD, Bergen. All estimates are given in 2006 Euros.
(N) Hospital-recruited
COPD patients
Population-recruited
COPD cases
Population-recruited
controls
P-value Patients-
controls**
P-value Patients-
cases**
P-value Cases-
controls**
Hospitalization, mean, median (iqr) 5278,
0 (4861)
1812,
0 (0)
1304,
0 (0)
<0.001 <0.001 0.810
Drug costs, mean, median (iqr) 2098,
1975 (1432)
1056,
866 (1161)
515,
245 (787)
<0.001 <0.001 <0.001
Contacts with healthcare
professionalsa; median (iqr)
1343,
667 (817)
759,
378 (864)
425,
172 (429)
<0.001 0.006 0.059
Pulmonary rehabilitation,
mean, median (iqr)
564,
0 (489)
202,
0 (0)
2,
0 (0)
<0.001 <0.001 0.003
Oxygen treatment, mean, median (iqr) 221,
0 (0)
0 0 <0.001 0.006 NA
Total costs, mean, median (iqr) 9503,
4595 (7059)
3829,
1478 (2143)
2245,
612(1488)
<0.001 <0.001 <0.001
** non-parametric median test.
Hospital-recruited COPD patients e selected COPD patients from the COPD register of a university hospital. Population-recruited COPD cases e subjects with COPD from a population-
based sample. Population-recruited controls e subjects without COPD, from a general population. All participants were at least 40 years old, and were ever-smokers. COPD is defined as
FEV1/FVC < 0.7 and FEV1 in % predicted < 80%. Control subjects have FEV1/FVC  0.7 and FEV1% predicted  80%.
Iqr e interquartile range (75th percentilee25th percentile).
NA e not applicable.
COPD e chronic obstructive pulmonary disease, defined as post-bronchodilator FEV1/FVC <0.7 and FEV1 <80% of predicted.
a Healthcare professionals includes: general practitioners, specialist physicians in private practice, hospital physicians at outpatient
clinic, emergency room visits, physiotherapists; home nursing services and house maid from the local healthcare authorities.
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Figure 1 Distribution of mean costs by 5 healthcare items, in
hospital-recruited patients, population-based cases and pop-
ulation-based controls.
Excessive costs of COPD 491The reduction in COPD costs when adjusting for comor-
bidities was similar to US studies varying from 24%12 to
46%,11 confirming that comorbidity is a dominant predictor
of excessive costs. Our study is the first to adjust for ERS
when calculating annual treatment-related costs for COPD.Table 4 Coefficients (95% CI) by gender, age, smoking habits,
treatment-related costs for population-recruited COPD cases and
recruited controls. All coefficients in 2006 Euros.
Covariate Coefficient (95% CI). Cas
controls (N Z 213).
Gender
Male Ref
Female 824 (390e1257)
Age, pr year 1 (21e24)
Smoking habit
Current smoker Ref
Ex-smoker 443 (20e907)
Education
University Ref
Secondary 122 (386e631)
Primary 274 (303e851)
Lung function
Normal ref
GOLD II 672 (191e1152)
GOLD III 1962 (866e3057)
GOLD IV 1543 (131e2955)
Constant 60 (1363e1244)
Hospital-recruited COPD patients e selected COPD patients from the
cases e subjects with COPD from a population-based sample. Popula
population. All participants were at least 40 years old, and were ev
Normal lung function: FEV1/FVC > 0.7 and FEV1% of predicted >80%.
GOLD stage III: FEV1/FVC < 0.7 and FEV1% of predicted 30e50%, GOLThe cost of V81 per exacerbation-event might be perceived
as low. Other authors have emphasized hospitalizations as
the cost-driving item of acute exacerbations of COPD.24,25
However, these studies estimated exacerbation costs
alone, thus not taking total annual costs of COPD into
account. The low frequency of hospital admissions in our
population suggests that many exacerbations were treated
by the patients themselves, their primary care physicians or
were left untreated.
No previous study has compared the costs of COPD in
a hospital-recruited population with costs in a population-
based sample. The majority of COPD cost studies have been
performed in selected populations.8e10,26e30 When aiming to
present costs for a general population, the threefold increase
in excessive costs when studying hospital-recruited COPD
patients implies a substantial bias for higher costs (Table4). As
Table 1 indicates, the population-based cases had less severe
disease, few comorbidities, more men, lower education and
they were slightly younger than the hospital-recruited COPD
patients. Our analyses were adjusted for disease stage,
smoking habits, comorbidities, gender, education and age.
However, we cannot exclude residual confounding. And some
of these covariates might have further reduced the observed
differences if the classifications weremore refined (e.g FEV1,
comorbidities, smoking habits).
The strengths of the present study were the detection of
spirometry defined COPD in a population-based sample,
inclusion of a control group to estimate excessive costs and
adjustment for comorbidities and excacerbations of COPD.
Possible weaknesses of our study might be the inclusion
criteria and recall bias. Our sample was restricted to
a subsample of the total population with only ever-smokerseducation and GOLD stage in median regression models of
controls; Hospital-recruited COPD patients and population-
es and Coefficient (95% CI). Patients
and controls (N Z 337).
Ref
441 (2e883)
51 (28e73)
Ref
207 (263e667)
Ref
438 (123e998)
26 (600e652)
Ref
2356 (1804e2908)
3370 (2725e4014)
6047 (5271e6824)
2525 (3893 to 1157)
COPD register of a university hospital. Population-recruited COPD
tion-recruited controls e subjects without COPD, from a general
er-smokers. COPD is defined as GOLD stage II and higher COPD.
GOLD stage II: FEV1/FVC < 0.7 and FEV1% of predicted 50e80%,
D stage IV: FEV1/FVC < 0.7 and FEV1% of predicted < 30%.
492 R. Nielsen et al.of at least 40 years of age. This was to improve compara-
bility regarding smoking habits between controls and COPD
cases. The sample size was also limited due to financial
resources. We excluded GOLD stage I based on the clinical
experience that these subjects less frequently were trou-
bled by respiratory symptoms. This view has been rein-
forced by the GOLD guidelines that has labelled stage IIeIV
clinically relevant disease.31 The BOLD studies and OLIN has
indicated that stage I disease accounts from 183 to 31%4 of
total COPD costs. If we had included stage I, costs per
patient would probably have been lower, whereas total
costs for the Norwegian society would have increased.
It is known that the GOLD-criteria underestimates COPD
in younger individuals and overestimates in the elderly.32
This might have led to an age-bias in our estimates. There
has been growing support to the lower limit of normal (LLN)
as diagnostic criterion for COPD.33 If we changed the
diagnostic criteria for our analyses, this could both result in
cases and controls changing status. The LLN for the
Norwegian reference equation used in our paper,15 mostly
lies higher than 0.7 for subjects above 40 years of age.
Our estimates relied on self-reported healthcare utili-
zation. The precision of categorical data on healthcare
utilization in COPD patients was high.21 However, contin-
uous variables on patients own expenses showed substan-
tial variation. In the current study we interviewed the
participants every three months, which is considered an
adequate recall period.34 All major cost items were
surveyed in terms of categorical questions and used official
co-payment-rates instead of self-reports. To minimize
observer-variability the interviewers went through exten-
sive training and there were comprehensive written
guidelines. Drug use was validated by participants having
their prescriptions or medication at hand during interviews.
According to the HCRHS,35 9.6% of ever-smoking inhabi-
tants aged 40 years or older in Norway have COPD stage IIeIV.
Thus, the national excessive costs would reach V105 millions
per year for Norwegian ever-smokers of 40 years and older.
The previous estimated costs of COPD in a BOLD initiated COI-
study in Norway4 was higher than in the present study, but
these costs are not directly comparable. First, the BOLD study
was based on attributed costs. Second, our study did not
include COPD GOLD stage I, which generated 1/3 of the costs
in the BOLD study. Third, none of the stage IV cases in the
present studywereadmitted tohospital orusedoxygen,which
might deflate the costs in this stage. Fourth, an estimation
based onmean instead of median costs, as in the BOLD study,
would also lead to increased costs. Finally, adding the preva-
lence of COPD in never-smokers aged above 40 years35 and
costs per COPD case as in ever-smokers with COPDwould raise
ourestimates toV124million. If individualsbetween27and40
years were included with a COPD stage IIeIV prevalence of
1.1%,35 costs would approximate V133 millions.
The OLIN studies3 estimated that attributable treatment-
related costs of COPD stage I and higher, for the Swedish
society were V452 millions per year. The Norwegian pop-
ulation is 1/2 of the Swedish and COPD stage I generated 18%
of the Swedish costs.3 Trying to adapt the Swedish results to
our Norwegian setting would thus reduce the OLIN estimate
to V185 millions. In addition post-bronchodilator COPD
prevalence estimates are 2/3 of pre-bronchodilator.35 Thus,
excessive costs of COPD in Norway were lower than theSwedish attributable costs, which indicate lower treatment-
related costs of COPD in Norway than in Sweden. This might
be due to higher utilization (hospital services and oxygen
therapy) in the Swedish survey, but methodological differ-
ences make direct comparison difficult.
To conclude, the annual median treatment-related
excessive costs of COPD GOLD stages IIeIV in Norway
ranged from V672 to V1962, depending on disease severity.
Economic measures can help identifying areas or pop-
ulations with large costs and potential savings, and thus
provide the foundation for cost evaluations. However, this
presupposes that the estimates can be generalised to the
society at large. We have shown that estimates based on
hospital-recruited COPD cases increased the excessive costs
of COPD by a factor of three, compared to estimates based
on population-recruited COPD cases.
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